Top

Published in:

01-10-2019 | Invited Review

The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside

Authors: Jonathan J. Duplisea, Sharada Mokkapati, Devin Plote, Kimberly S. Schluns, David J. McConkey, Seppo Yla-Herttuala, Nigel R. Parker, Colin P. Dinney

Published in: World Journal of Urology | Issue 10/2019

Abstract

Background and Purpose

BCG unresponsive bladder cancer is an inherently resistant disease state for which the preferred treatment is radical cystectomy. To date, no effective intravesical therapies exist for patients who possess these resistant tumors. For this reason, many research groups are actively investigating/testing novel therapeutic agents to aid in bladder preservation for this patient population. This review article describes our 15-year experience developing and testing IFN-based gene therapy.

Methods

A comprehensive review was performed of all studies pertaining to IFN-based gene therapy for non-muscle invasive bladder cancer from 2003 to 2018.

Results and Conclusions

Over the past two decades, gene therapy has evolved into a powerful tool in our fight against cancer. After overcoming the initial barriers associated with gene delivery to the bladder, we have made significant strides forward in developing this novel therapeutic strategy for the treatment of this inherently resistant disease state. Our results to date are very encouraging; however, much work lies ahead to better understand and optimize this novel approach for treating non-muscle invasive bladder.

Kaufman DS, Shipley WU, Feldman AS (2009) Bladder cancer. Lancet (Lond, Engl) 374(9685):239–249. https://doi.org/10.1016/s0140-6736(09)60491-8 CrossRef

Siegel RL, Miller KD, Jemal A (2017) Cancer statistics 2017. CA Cancer J Clin 67(1):7–30. https://doi.org/10.3322/caac.21387 CrossRefPubMed

Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM, Hernandez V, Kaasinen E, Palou J, Roupret M, van Rhijn BW, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71(3):447–461. https://doi.org/10.1016/j.eururo.2016.05.041 CrossRefPubMed

Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, Pruthi R, Quale DZ, Ritch CR, Seigne JD, Skinner EC, Smith ND, McKiernan JM (2016) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol 196(4):1021–1029. https://doi.org/10.1016/j.juro.2016.06.049 CrossRefPubMed

Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA (2017) Bladder cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Nat Compr Cancer Netw JNCCN 15(10):1240–1267. https://doi.org/10.6004/jnccn.2017.0156 CrossRef

Jarow J, Maher VE, Tang S, Ibrahim A, Kim G, Sridhara R, Pazdur R (2015) Development of systemic and topical drugs to treat non-muscle invasive bladder cancer. Bladder Cancer (Amst, Neth) 1(2):133–136. https://doi.org/10.3233/blc-150016 CrossRef

Prout GR Jr, Koontz WW Jr, Coombs LJ, Hawkins IR, Friedell GH (1983) Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa. J Urol 130(4):677–680CrossRefPubMed

Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M (2000) Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 163(3):761–767CrossRefPubMed

Kamat AM, Colombel M, Sundi D, Lamm D, Boehle A, Brausi M, Buckley R, Persad R, Palou J, Soloway M, Witjes JA (2017) BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. Nat Rev Urol 14(4):244–255. https://doi.org/10.1038/nrurol.2017.16 CrossRefPubMed

10.

Steinberg RL, Thomas LJ, Mott SL, O’Donnell MA (2016) Bacillus Calmette-Guerin (BCG) treatment failures with non-muscle invasive bladder cancer: a data-driven definition for BCG unresponsive disease. Bladder Cancer (Amst, Neth) 2(2):215–224. https://doi.org/10.3233/blc-150039 CrossRef

11.

Nieder AM, Brausi M, Lamm D, O’Donnell M, Tomita K, Woo H, Jewett MA (2005) Management of stage T1 tumors of the bladder: International Consensus Panel. Urology 66(6 Suppl 1):108–125. https://doi.org/10.1016/j.urology.2005.08.066 CrossRefPubMed

12.

Lerner SP, Dinney C, Kamat A, Bivalacqua TJ, Nielsen M, O’Donnell M, Schoenberg MP, Steinberg G (2015) Clarification of bladder cancer disease states following treatment of patients with intravesical BCG. Bladder Cancer (Amster, Neth) 1(1):29–30. https://doi.org/10.3233/blc-159002 CrossRef

13.

US Department of Health and Human Service Food and Drug administration (2018) BCG unresponsive non-muscle invasive bladder cancer—developing drugs and biologics for treatment—a guideline for industry. https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandgeneTherapy/default/htm

14.

Siddiqui MR, Grant C, Sanford T, Agarwal PK (2017) Current clinical trials in non-muscle invasive bladder cancer. Urol Oncol 35(8):516–527. https://doi.org/10.1016/j.urolonc.2017.06.043 CrossRefPubMedPubMedCentral

15.

Papageorgiou A, Dinney CP, McConkey DJ (2007) Interferon-alpha induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells. Cancer Biol Ther 6(6):872–879CrossRefPubMed

16.

von Marschall Z, Scholz A, Cramer T, Schafer G, Schirner M, Oberg K, Wiedenmann B, Hocker M, Rosewicz S (2003) Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 95(6):437–448CrossRef

17.

Dinney CP, Bielenberg DR, Perrotte P, Reich R, Eve BY, Bucana CD, Fidler IJ (1998) Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Can Res 58(4):808–814

18.

Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ (1999) Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 5(10):2726–2734PubMed

19.

Joudi FN, Smith BJ, O’Donnell MA (2006) Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 24(4):344–348. https://doi.org/10.1016/j.urolonc.2005.11.026 CrossRefPubMed

20.

Lamm D, Brausi M, O’Donnell MA, Witjes JA (2014) Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer. Urol Oncol 32(1):35.e21–35.e30. https://doi.org/10.1016/j.urolonc.2013.02.010 CrossRef

21.

Malmstrom PU (2002) A randomized comparative dose-ranging study of interferon-alpha and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder. BJU Int 89(7):681–686CrossRefPubMed

22.

Rajala P, Kaasinen E, Raitanen M, Liukkonen T, Rintala E (2002) Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study–FinnBladder III long-term results. J Urol 168(3):981–985. https://doi.org/10.1097/01.ju.0000026417.33622.7d CrossRefPubMed

23.

Torti FM, Shortliffe LD, Williams RD, Pitts WC, Kempson RL, Ross JC, Palmer J, Meyers F, Ferrari M, Hannigan J et al (1988) Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study. J Clin Oncol 6(3):476–483. https://doi.org/10.1200/jco.1988.6.3.476 CrossRefPubMed

24.

Correa AF, Theisen K, Ferroni M, Maranchie JK, Hrebinko R, Davies BJ, Gingrich JR (2015) The role of interferon in the management of BCG refractory nonmuscle invasive bladder cancer. Adv Urol 2015:656918. https://doi.org/10.1155/2015/656918 CrossRefPubMedPubMedCentral

25.

Shepherd AR, Shepherd E, Brook NR (2017) Intravesical Bacillus Calmette-Guerin with interferon-alpha versus intravesical Bacillus Calmette-Guerin for treating non-muscle-invasive bladder cancer. Cochrane Database Syst Rev 3:Cd012112. https://doi.org/10.1002/14651858.cd012112.pub2 CrossRefPubMed

26.

Belldegrun AS, Franklin JR, O’Donnell MA, Gomella LG, Klein E, Neri R, Nseyo UO, Ratliff TL, Williams RD (1998) Superficial bladder cancer: the role of interferon-alpha. J Urol 159(6):1793–1801CrossRefPubMed

27.

Kaji EH, Leiden JM (2001) Gene and stem cell therapies. JAMA 285(5):545–550CrossRefPubMed

28.

Walther W, Schlag PM (2013) Current status of gene therapy for cancer. Curr Opin Oncol 25(6):659–664. https://doi.org/10.1097/cco.0000000000000004 CrossRefPubMed

29.

Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, Karson EM, Lotze MT, Yang JC, Topalian SL et al (1990) Gene transfer into humans–immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 323(9):570–578. https://doi.org/10.1056/nejm199008303230904 CrossRefPubMed

30.

Wirth T, Parker N, Yla-Herttuala S (2013) History of gene therapy. Gene 525(2):162–169. https://doi.org/10.1016/j.gene.2013.03.137 CrossRefPubMed

31.

Wysocki PJ, Karczewska-Dzionk A, Mackiewicz-Wysocka M, Mackiewicz A (2004) Human cancer gene therapy with cytokine gene-modified cells. Expert Opin Biol Ther 4(10):1595–1607. https://doi.org/10.1517/14712598.4.10.1595 CrossRefPubMed

32.

Baldo BA (2014) Side effects of cytokines approved for therapy. Drug Saf 37(11):921–943. https://doi.org/10.1007/s40264-014-0226-z CrossRefPubMedPubMedCentral

33.

Jonasch E, Haluska FG (2001) Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6(1):34–55CrossRefPubMed

34.

Bass C, Cabrera G, Elgavish A, Robert B, Siegal GP, Anderson SC, Maneval DC, Curiel DT (1995) Recombinant adenovirus-mediated gene transfer to genitourinary epithelium in vitro and in vivo. Cancer Gene Ther 2(2):97–104PubMed

35.

Klingler CH (2016) Glycosaminoglycans: how much do we know about their role in the bladder? Urologia 83(Suppl 1):11–14. https://doi.org/10.5301/uro.5000184 CrossRefPubMed

36.

Engler H, Anderson SC, Machemer TR, Philopena JM, Connor RJ, Wen SF, Maneval DC (1999) Ethanol improves adenovirus-mediated gene transfer and expression to the bladder epithelium of rodents. Urology 53(5):1049–1053CrossRefPubMed

37.

Connor RJ, Engler H, Machemer T, Philopena JM, Horn MT, Sutjipto S, Maneval DC, Youngster S, Chan TM, Bausch J, McAuliffe JP, Hindsgaul O, Nagabhushan TL (2001) Identification of polyamides that enhance adenovirus-mediated gene expression in the urothelium. Gene Ther 8(1):41–48. https://doi.org/10.1038/sj.gt.3301348 CrossRefPubMed

38.

Yamashita M, Rosser CJ, Zhou JH, Zhang XQ, Connor RJ, Engler H, Maneval DC, Karashima T, Czerniak BA, Dinney CP, Benedict WF (2002) Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer. Cancer Gene Ther 9(8):687–691. https://doi.org/10.1038/sj.cgt.7700488 CrossRefPubMed

39.

Iqbal Ahmed CM, Johnson DE, Demers GW, Engler H, Howe JA, Wills KN, Wen SF, Shinoda J, Beltran J, Nodelman M, Machemer T, Maneval DC, Nagabhushan TL, Sugarman BJ (2001) Interferon alpha2b gene delivery using adenoviral vector causes inhibition of tumor growth in xenograft models from a variety of cancers. Cancer Gene Ther 8(10):788–795. https://doi.org/10.1038/sj.cgt.7700364 CrossRefPubMed

40.

Benedict WF, Tao Z, Kim CS, Zhang X, Zhou JH, Adam L, McConkey DJ, Papageorgiou A, Munsell M, Philopena J, Engler H, Demers W, Maneval DC, Dinney CP, Connor RJ (2004) Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol Ther J Am Soc Gene Ther 10(3):525–532. https://doi.org/10.1016/j.ymthe.2004.05.027 CrossRef

41.

Izawa JI, Sweeney P, Perrotte P, Kedar D, Dong Z, Slaton JW, Karashima T, Inoue K, Benedict WF, Dinney CP (2002) Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin Cancer Res 8(4):1258–1270PubMed

42.

Benedict WF, Fisher M, Zhang XQ, Yang Z, Munsell MF, Dinney CN (2014) Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFNalpha/Syn3 treatment in a phase l study. Cancer Gene Ther 21(3):91–94. https://doi.org/10.1038/cgt.2014.1 CrossRefPubMedPubMedCentral

43.

Zhang X, Dong L, Chapman E, Benedict WF (2008) Conditioned medium from Ad-IFN-alpha-infected bladder cancer and normal urothelial cells is cytotoxic to cancer cells but not normal cells: further evidence for a strong bystander effect. Cancer Gene Ther 15(12):817–822. https://doi.org/10.1038/cgt.2008.53 CrossRefPubMedPubMedCentral

44.

Zhang X, Yang Z, Dong L, Papageorgiou A, McConkey DJ, Benedict WF (2007) Adenoviral-mediated interferon alpha overcomes resistance to the interferon protein in various cancer types and has marked bystander effects. Cancer Gene Ther 14(3):241–250. https://doi.org/10.1038/sj.cgt.7701011 CrossRefPubMed

45.

Connor RJ, Anderson JM, Machemer T, Maneval DC, Engler H (2005) Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: a study in rats evaluating dosing regimens. Urology 66(1):224–229. https://doi.org/10.1016/j.urology.2005.02.015 CrossRefPubMed

46.

Tao Z, Connor RJ, Ashoori F, Dinney CP, Munsell M, Philopena JA, Benedict WF (2006) Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation. Cancer Gene Ther 13(2):125–130. https://doi.org/10.1038/sj.cgt.7700865 CrossRefPubMed

47.

Vellinga J, Smith JP, Lipiec A, Majhen D, Lemckert A, van Ooij M, Ives P, Yallop C, Custers J, Havenga M (2014) Challenges in manufacturing adenoviral vectors for global vaccine product deployment. Hum Gene Ther 25(4):318–327. https://doi.org/10.1089/hum.2014.007 CrossRefPubMed

48.

Dinney CP, Fisher MB, Navai N, O’Donnell MA, Cutler D, Abraham A, Young S, Hutchins B, Caceres M, Kishnani N, Sode G, Cullen C, Zhang G, Grossman HB, Kamat AM, Gonzales M, Kincaid M, Ainslie N, Maneval DC, Wszolek MF, Benedict WF (2013) Phase I trial of intravesical recombinant adenovirus mediated interferon-alpha2b formulated in Syn3 for Bacillus Calmette-Guerin failures in nonmuscle invasive bladder cancer. J Urol 190(3):850–856. https://doi.org/10.1016/j.juro.2013.03.030 CrossRefPubMedPubMedCentral

49.

Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh LI, Downs TM, Gomella LG, Kamat AM, Lotan Y, Svatek RS, Bivalacqua TJ, Grubb RL 3rd, Krupski TL, Lerner SP, Woods ME, Inman BA, Milowsky MI, Boyd A, Treasure FP, Gregory G, Sawutz DG, Yla-Herttuala S, Parker NR, Dinney CPN (2017) Intravesical rAd-IFNalpha/Syn3 for patients with high-grade, Bacillus Calmette-Guerin-refractory or relapsed non-muscle-invasive bladder cancer: a Phase II Randomized Study. J Clin Oncol 35(30):3410–3416. https://doi.org/10.1200/jco.2017.72.3064 CrossRefPubMedPubMedCentral

50.

Dinney CP, Greenberg RE, Steinberg GD (2013) Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guerin. Urol Oncol 31(8):1635–1642. https://doi.org/10.1016/j.urolonc.2012.04.010 CrossRefPubMed

51.

Packiam VT, Lamm DL, Barocas DA, Trainer A, Fand B, Davis RL 3rd, Clark W, Kroeger M, Dumbadze I, Chamie K, Kader AK, Curran D, Gutheil J, Kuan A, Yeung AW, Steinberg GD (2017) An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results. Urol Oncol 45:54. https://doi.org/10.1016/j.urolonc.2017.07.005 CrossRef

Title: The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside
Authors: Jonathan J. Duplisea
Sharada Mokkapati
Devin Plote
Kimberly S. Schluns
David J. McConkey
Seppo Yla-Herttuala
Nigel R. Parker
Colin P. Dinney
Publication date: 01-10-2019
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 10/2019
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-018-2553-7

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside

Abstract

Background and Purpose

Methods

Results and Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background and Purpose

Methods

Results and Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2019

Association of training level and outcome of software-based image fusion-guided targeted prostate biopsies

Mutations in CDKN2A and the FGFR3 genes on bladder cancer diagnosis: a systematic review and meta-analysis

Endoscopic observations as a tool to define underlying pathology in kidney stone formers

Visceral obesity in Asian living kidney donors significantly impacts early renal function after donor nephrectomy

Prognostic impact of non-adherence to follow-up cystoscopy in non-muscle-invasive bladder cancer (NMIBC)

Trends in utilization and perioperative outcomes in live donor nephrectomies: a multi-surgical discipline analysis